investors.xoma.com
Investor Relations | XOMA CorporationThe Investor Relations website contains information about XOMA Corporation's business for stockholders, potential investors, and financial analysts.
http://investors.xoma.com/
The Investor Relations website contains information about XOMA Corporation's business for stockholders, potential investors, and financial analysts.
http://investors.xoma.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Tuesday
LOAD TIME
0.2 seconds
16x16
PAGES IN
THIS WEBSITE
20
SSL
EXTERNAL LINKS
11
SITE IP
23.55.218.214
LOAD TIME
0.191 sec
SCORE
6.2
Investor Relations | XOMA Corporation | investors.xoma.com Reviews
https://investors.xoma.com
The Investor Relations website contains information about XOMA Corporation's business for stockholders, potential investors, and financial analysts.
investors.xoma.com
XOMA Corporation - Quarterly Results
http://investors.xoma.com/results.cfm
XOMA Reports Second Quarter 2016 Achievements and Financial Results. XOMA Reports First Quarter 2016 Operational Achievements and Financial Results. XOMA Reports Fourth Quarter and Full-Year 2015 Financial Results. XOMA Provides Corporate Update and Reports Financial Results for Third Quarter 2015. XOMA Reports Financial Results for Second Quarter 2015. XOMA Reports First Quarter 2015 Achievements and Financial Results. XOMA Reports First Quarter 2014 Operational Highlights and Financial Results. XOMA Re...
XOMA Reports Financial Results for Second Quarter 2015 (NASDAQ:XOMA)
http://investors.xoma.com/releasedetail.cfm?ReleaseID=926423
Laquo; Previous Release. Next Release ». August 6, 2015. XOMA Reports Financial Results for Second Quarter 2015. BERKELEY, Calif., Aug. 6, 2015 (GLOBE NEWSWIRE) - XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today provided a corporate update and reported its financial results for the quarter ended June 30, 2015. For the second quarter of 2015, XOMA had a net loss of $23.8 million, compared with a net loss of $11.9 million for the second quar...On Ju...
XOMA Corporation - RSS News Feeds
http://investors.xoma.com/rss.cfm
Really Simple Syndication (RSS) is a format designed for sharing web content such as headlines. An RSS feed highlights fresh material for you, so you don't have to repeatedly check a site yourself for updates. How do I use RSS? To make use of RSS, you'll need an RSS reader, or aggregator. An RSS aggregator can be a stand-alone application, or a plug-in for another program you already use, such as Microsoft Outlook. Some web browsers, such as Firefox. To view a feed in your RSS Aggregator:.
XOMA Corporation - Download Library
http://investors.xoma.com/downloads.cfm
Quickly sort and find the exact file you need here. Send the files directly into your Shareholder Briefcase or read and right click "save target as" individual files. Nominating and Governance Committee Charter. Showing 1-10 of 19. Add file to Briefcase. 2910 Seventh Street - Berkeley, CA 94710 - (510) 204-7200.
XOMA Corporation - Investor Relations
http://investors.xoma.com/index.cfm
XOMA Corporation is a biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company’s innovative product candidates are the result of its expertise in developing ground-breaking monoclonal antibodies, which have created new opportunities to potentially treat a wide range of endocrine diseases. XOMA 129, a novel antibody fragment (Fab) from the XMetD program, designed as a potential treatment for severe acute hypoglycemia. Preclinical data was presented at the Endocr...
TOTAL PAGES IN THIS WEBSITE
20
Pipeline - XOMA
http://www.xoma.com/content/pipeline/overview.htm
XOMA has leveraged deep expertise in the discovery and development of human and humanized monoclonal antibodies to create a pipeline of product candidates with the potential to treat a variety of endocrine diseases. Congenital hyperinsulinism and P. Short-acting reversal of drug-induced hypoglycemia. Hyperparathyroidism, Malignancy induced hypercalcemia. 2910 Seventh Street - Berkeley, CA 94710 - (510) 204-7200.
Pipeline - XOMA
http://www.xoma.com/content/pipeline/gevokizumab.htm
Gevokizumab is a potent monoclonal antibody with the potential to treat patients with a wide variety of inflammatory diseases and other diseases. More information on all of XOMA's clinical programs can be found at www.clinicaltrials.gov. Or www.clinicaltrialsregister.eu. 2910 Seventh Street - Berkeley, CA 94710 - (510) 204-7200.
Partnering and Licensing - XOMA
http://www.xoma.com/content/partnering-and-licensing/overview.htm
Partnering and Licensing Opportunities. XOMA is reviewing strategic options for assets that are outside its scope of focus through license, sale, or other corporate structure. Current agreements include:. Multiple License and Collaboration Agreements. Licensed our first-in-class TGF β. Immuno-oncology antibody program to Novartis for an upfront payment of $37 million, potential milestone payments of up to $480 million and tiered royalties up to low double digits. Certolizumab pegol) for rheumatoid arthri...
Antibody Platform - XOMA
http://www.xoma.com/content/antibody-platform/overview.htm
XOMA’s extensive antibody expertise includes antibody discovery, optimization as well as cell line and process development. We combine access to multiple antibody discovery and development technologies with intellectual property, technical expertise and know-how, and integrated infrastructure to gain a unique advantage in the rapid and efficient development of fully human therapeutic antibodies with unique differentiating properties. ADAPT (Antibody Discovery Advanced Platform Technologies).
About XOMA
http://www.xoma.com/content/about-xoma/overview.htm
XOMA Corporation (Nasdaq: XOMA) is a biotechnology company focused on the discovery and development of monoclonal antibody-based therapeutics. XOMA Corporation is a biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company’s innovative product candidates are the result of its expertise in developing ground-breaking monoclonal antibodies, which have created new opportunities to potentially treat a wide range of endocrine diseases. Preclinical data was presented at th...
XOMA
http://www.xoma.com/index.htm
XOMA Ltd. (Nasdaq: XOMA) is a biotechnology company focused on the discovery, development and manufacturing of monoclonal antibody-based therapeutics for serious unmet medical needs. XOMA's world-class monoclonal antibody technologies have contributed to the development of marketed biologics with a total of more than $1 billion in annual sales and for which XOMA received substantial royalties. XOMA’s extensive antibody expertise includes antibody discovery, optimization, cell line and process development.
TOTAL LINKS TO THIS WEBSITE
11
Xactly Corporation - Investors - Overview
1866GO.XACTLY (469.2285). Xactly is a leading provider of enterprise-class, cloud-based, incentive compensation SaaS solutions for employee and SPM. We empower organizations to incentivize employees, mitigate risk, make data-backed decisions, design better comp plans, and inspire performance. August 11, 2015. EWAY Selects Xactly to Motivate Sales and Boost Employee Satisfaction. August 5, 2015. Xactly Named Top Incentive Management Provider in CRM Magazine Market Leader Awards. August 4, 2015. Excellence...
Investor Overview - Xbiotech Investor Relations
Data provided by Nasdaq. Minimum 15 minutes delayed. XBiotech is building on a foundation of remarkable new therapies, innovative approaches to commercialization and a commitment to realizing treatments for unmet medical needs worldwide. XBiotech Completes Enrollment for Xilonix(TM) Phase III Registration Study in Europe. XBiotech Announces Expansion of Global Phase 3 Registration Study in Europe using Xilonix(TM) for Treatment of Metastatic Colorectal Cancer. There are currently no events scheduled.
IntegrateIR
Enter any ticker symbol here to see the live quote and chart tools in action. It gives you the power. To provide dynamic real-time and delayed quotes, charts, filings, news and disclosure tools to your customers and shareholders. Allowing you to provide all these things at a fraction of the cost of traditional internal methods. It helps your company adhere. To recommended regulatory guidelines and disclosure rules. Your regulatory filings through automation. It can be seamlessly. It can be quickly. This ...
Investor Relations - Xencor, Inc.
IIb Immune Inhibitor Technology. Cytotoxic Fc Domain Technology. Xencor Inc. 2015 R&D Day. June 26, 2015. EULAR 2015 Poster Presentation. June 12, 2015. June 3, 2015. Aug 4, 2015. Xencor Reports Second Quarter 2015 Financial and Operating Results. Aug 4, 2015. Xencor to Present at 2015 Wedbush PacGrow Healthcare Conference. Aug 11, 2015 at 10:55 AM ET. 2015 Wedbush PacGrow Healthcare Conference. Aug 4, 2015 at 4:30 PM ET. Q2 2015 Xencor, Inc. Earnings Conference Call.
Corporate Overview - Xenia Hotels & Resorts
Email Alerts / Investor Information. 021 - 1.05 %. As of August 18, 2015 2:01 PM -. Minimum 20 minute delay. Second Quarter 2015 Earnings Conference Call. Thursday, August 13, 2015. Live Toll-Free (855) 656-0921. Xenia Hotels and Resorts, Inc. Xenia Hotels and Resorts Reports Second Quarter 2015 Results. Xenia Hotels and Resorts Agrees To Acquire The Hotel Commonwealth In Boston, Massachusetts. The ONE Group Announces STK Rebel Will Open in Andaz San Diego. Xenia Hotels and Resorts, Inc. Orlando, FL 32801.
Investor Relations | XOMA Corporation
Skip to main navigation. Assets Available for Licensure. The Company intends to build upon its current portfolio by employing multiple strategies to acquire additional license interests (i.e. milestones and royalties) in partner-funded programs. If XOMA license holders successfully advance product candidates towards regulatory approval and ultimately commercialization, the Company will receive milestone payments and royalty revenues without any additional investment. Mar 29, 2018 5:36 PM EDT. Mar 07, 2018.
Investors | Investors | XPO Logistics
Skip to main content. Stock Quote and Chart. Code of Business Conduct and Ethics. Senior Officer Code of Business Conduct and Ethics. XPO serves more than 30,000 customers with a highly integrated network of over 54,000 employees and 887 locations in 27 countries. The company's corporate headquarters is in Greenwic. XPO Logistics Announces Second Quarter 2015 Results. XPO Logistics Schedules Second Quarter 2015 Conference Call for Thursday, August 6, 2015. XPO Logistics Acquires Norbert Dentressangle.
Xylem: Let's Solve Water | Investor Relations | Overview
Xylem Inc. to participate in the 2015 Canaccord Genuity 35th Annual Growth Conference. Xylem Inc. reports second quarter 2015 earnings. Xylem awarded $6M rental contract for Panama Canal expansion project. Xylem Inc. Chief Financial Officer Resigns to Accept Another Opportunity. Company Provides Preliminary Second Quarter 2015 Financial Results RYE BROOK, N.Y.- (BUSINESS WIRE)- Jul. 13, 2015- Xylem Inc. (NYSE:XYL), a leading global water technology company dedicated to solving the world’s...Texas student...
investors.xyz
The Sponsored Listings displayed above are served automatically by a third party. Neither the service provider nor the domain owner maintain any relationship with the advertisers. In case of trademark issues please contact the domain owner directly (contact information can be found in whois).
SOCIAL ENGAGEMENT